Accumetrics, Inc., a developer and marketer of a point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, has raised an additional $7m in a financing round first announced in the Fall of 2009.
This brings the total amount raised by the company in this round to $24m.
The capital infusion comes primarily from the company’s existing investors, including Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Rivervest and Kaiser Permanente.
Accumetrics’ VerifyNow System helps physicians assess patients’ response to all major types of antiplatelet therapies such as aspirin, P2Y12 inhibitors and GP IIb/IIIa inhibitors. It is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.
The funds will be used to fund the completion of a number of key milestones and continued expansion of its global commercialization efforts.